Seeking Alpha


Send Message
View as an RSS Feed
View Avoc's Comments BY TICKER:
Latest  |  Highest rated
  • Ariad +13% as BMO upgrades, assets likely to attract M&A interest [View news story]
    Well, when the only other options is death, I think I'd run the risk of using the medication.
    Jan 25 07:42 PM | Likes Like |Link to Comment
  • These Small-Cap BioPharma Companies Have Catalysts Upcoming [View article]
    It says so in the PR.
    Dec 23 03:08 PM | 1 Like Like |Link to Comment
  • Treating Melanoma: Only The Best Shall Survive [View article]
    Worth noting - OncoSec is licensing technology developed by Inovio. Under the agreement, Inovio will receive a royalty on any future product sales.
    Nov 13 04:02 PM | 5 Likes Like |Link to Comment
  • Stratasys Set To Beat Top And Bottom Line Estimates [View article]
    Why not both?
    Nov 5 11:50 AM | Likes Like |Link to Comment
  • Why Are The Shorts Picking On Inovio? [View article]
    You are aware that Roche is footing the bill for two of its clinical candidates, right? They will receive a milestone payment by the end of this year once they begin the phase I study, and another milestone payment for the other phase I study in the first half of next year.
    Not to forget, the CEO has multiple times confirmed that they are in further advanced talks with other big pharma for partnerships.

    The risk of dillution in the first half of 2014 is microscopic.
    Oct 23 08:02 AM | 17 Likes Like |Link to Comment
  • Inovio's Partnership And Its Many Benefits [View article]
    It was from the presentation yesterday - you can find the presentation on inovios website
    Sep 13 11:03 AM | 1 Like Like |Link to Comment
  • Inovio's Partnership And Its Many Benefits [View article]
    Risk of dilution? They have enough cash to run through end of 2015, and that is without any milestone payments by Roche. The risk of dilution that is 'noted by others' are made by shorts since they don't have anything else to pin their hopes on by now.
    Sep 12 07:38 AM | 1 Like Like |Link to Comment
  • Inovio - Dilution And Catalysts Make It A Promising Short [View article]
    Much further than Q3 2015, as the development costs have been picked up by Roche.
    Sep 10 10:54 AM | 6 Likes Like |Link to Comment
  • Inovio And OncoSec Retain Higher Valuations, More Data Anticipated Soon [View article]
    Just like last friday, when it jumped 15% for no apparant reason.
    Sep 9 04:03 PM | Likes Like |Link to Comment
  • Celsion's A Fighter [View article]
    Only thing I personally do not understand, is why in the PR made on the 23rd of april they state:

    "The Company has engaged Cantor Fitzgerald & Co. to conduct a comprehensive review of merger and acquisition opportunities with the goal of identifying novel products with high potential, or companies, for Celsion to acquire."

    Why would they wish to acquire new products if they believe that Thermodox works?
    May 2 07:00 PM | Likes Like |Link to Comment
  • Inovio's Hepatitis C Data: What Does It Really Mean? [View article]
    Inovio and Chrontec are two different companies. Inovio has given Chrontec the right to use its previous gen eletroporation technology. In return, Inovio has partial ownership of the vaccine which Chrontec is developing. Apart from that, the two companies have nothing in common and do not influence eachother in any way.
    Apr 5 10:00 AM | 4 Likes Like |Link to Comment
  • Refocused, Reframed And Patiently Awaiting Celsion's Real Results After This Week's Chaos [View article]
    Its MLK day on monday - there will be no trading.
    Jan 19 01:31 AM | Likes Like |Link to Comment
  • Refocused, Reframed And Patiently Awaiting Celsion's Real Results After This Week's Chaos [View article]
    Jan 18 01:11 PM | 3 Likes Like |Link to Comment
  • Buy These Cheap, Below $7 Tech Stocks Now For A 'January Effect' Rally [View article]
    I wouldn't touch Zynga with a ten-foot pole. Until they bring in a new management and change their work culture, it will just go further down. There is a reason why Zynga is one of the most hated companies in the game-development world.
    Dec 30 11:34 AM | 1 Like Like |Link to Comment
  • Acadia Pharmaceuticals: Making Big Waves [View article]
    I am bullish on CLSN.

    Part of the reason why ThermoDox was allowed to skip phase II trials is because its not a new drug, but a new drug delivery platform. As such, the safety profile of the drug itself is very well documented and didnt require a phase II trial.

    The thing that will be interesting to see, is wether or not the high dosage of Doxorubicin will have any negative side-effects that would break ThermoDox. I don't believe such thing will happen, but one should never be too certain in Biotechs.
    Dec 7 03:07 PM | Likes Like |Link to Comment